Would you use neratinib in a very-high risk Her-2 positive breast cancer patient who is ER-?

ExteNET trial of neratinib, given for one year after completion of adjuvant trastuzumab, showed a small improvement in DFS. No OS benefit. HR-positive patients derived most of this small DFS benefit. I don’t think HR-negative patients will benefit at all. But for patients who are at incredibly high ...

No